Profile data is unavailable for this security.
About the company
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is undertaking preclinical research and development activities for the SCA platform.
- Revenue in USD (TTM)0.00
- Net income in USD-19.94m
- Incorporated2016
- Employees4.00
- Location180 Life Sciences Corp3000 El Camino Real, Bldg 4, Ste 200PALO ALTO 94306United StatesUSA
- Phone+1 (650) 507-0669
- Fax+1 (302) 636-5454
- Websitehttps://180lifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yield10 Bioscience Inc | 60.00k | -14.46m | 1.36m | 29.00 | -- | -- | -- | 22.60 | -50.04 | -50.04 | 0.1815 | -4.95 | 0.01 | -- | 4.00 | 2,068.97 | -241.08 | -91.26 | -524.02 | -108.09 | -- | -- | -24,091.67 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
| Neubase Therapeutics Inc | 0.00 | -13.73m | 1.42m | 37.00 | -- | 0.1543 | -- | -- | -7.78 | -7.78 | 0.00 | 2.45 | 0.00 | -- | -- | -- | -53.51 | -- | -64.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Agentix Corp | 0.00 | -1.01m | 1.42m | -- | -- | -- | -- | -- | -0.0253 | -0.0253 | 0.00 | -0.071 | 0.00 | -- | -- | -- | -907.08 | -- | -- | -- | -- | -- | -- | -- | -- | -96.41 | -- | -- | -- | -- | -- | -- | -- | -- |
| Drazcanna Inc | 2.05m | -5.71m | 1.47m | -- | -- | -- | -- | 0.7192 | -0.7024 | -0.7024 | 0.2492 | 0.1004 | 0.685 | -- | 23.88 | -- | -191.19 | -- | -643.20 | -- | -11.20 | -- | -279.10 | -- | -- | -33.04 | 0.2445 | -- | -- | -- | -- | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -19.94m | 1.49m | 4.00 | -- | -- | -- | -- | -64.01 | -64.01 | 0.00 | -0.2389 | 0.00 | -- | -- | 0.00 | -160.06 | -42.39 | -280.99 | -56.41 | -- | -- | -- | -- | -- | -- | 1.14 | -- | -- | -- | 48.52 | -- | -- | -- |
| CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 1.54m | 0.00 | -- | 0.8665 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
| GRI Bio Inc | 0.00 | -12.77m | 1.59m | 4.00 | -- | 0.4798 | -- | -- | -26.90 | -26.90 | 0.00 | 0.8753 | 0.00 | -- | -- | 0.00 | -382.23 | -192.93 | -869.57 | -353.99 | -- | -- | -- | -37,650.49 | -- | -16.80 | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
| SOHM Inc | -100.00bn | -100.00bn | 1.60m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Mallinckrodt PLC | 1.91bn | -1.49bn | 1.60m | 2.80k | -- | -- | -- | 0.0008 | -161.65 | -161.63 | 89.63 | 55.44 | 0.4062 | 1.57 | 4.94 | 681,821.40 | -31.61 | -12.49 | -36.10 | -15.85 | 26.22 | 35.68 | -77.83 | -44.38 | 1.63 | -0.3456 | 0.6164 | -- | -2.53 | -10.31 | -83.00 | -- | -- | -- |
| Cannabis Suisse Corp | 30.00k | -254.75k | 1.62m | -- | -- | -- | -- | 54.07 | -0.0057 | -0.0057 | 0.0007 | -0.0103 | 0.0675 | -- | -- | -- | -57.35 | -149.71 | -238.71 | -- | 8.37 | -39.11 | -849.17 | -427.20 | -- | -13.57 | 3.38 | -- | 28.70 | 9.00 | -87.10 | -- | -- | -- |
| Stemcell Holdings Inc | 9.98m | 3.10m | 1.64m | -- | -- | -- | 0.5008 | 0.1645 | 0.00008 | 0.00008 | 0.0003 | 0.0002 | 1.12 | -- | 5.20 | -- | 34.90 | -- | 68.19 | -- | 77.19 | -- | 31.04 | -- | -- | -- | 0.00 | -- | 85.10 | -- | 71.82 | -- | -- | -- |
| LadRx Corp | 0.00 | 331.63k | 1.67m | 2.00 | 5.75 | 15.53 | 4.85 | -- | 0.5857 | 0.5857 | 0.00 | 0.2168 | 0.00 | -- | -- | 0.00 | 17.58 | -58.97 | 480.72 | -78.44 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 106.96 | -- | -- | -- |
| Bluejay Diagnostics Inc | 0.00 | -7.41m | 1.68m | 10.00 | -- | -- | -- | -- | -6.69 | -6.69 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -92.89 | -- | -113.91 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -7.07 | -- | -- | -- |
| Procyon Corp | 4.70m | -314.48k | 1.69m | 17.00 | -- | 0.7597 | -- | 0.3597 | -0.0388 | -0.0388 | 0.5804 | 0.2901 | 1.40 | 1.95 | 8.58 | 276,481.20 | -8.90 | 3.52 | -10.60 | 4.23 | 77.60 | 73.30 | -6.35 | 2.52 | 2.70 | -- | 0.00 | -- | -3.22 | 3.11 | 70.44 | -- | 30.98 | -- |
| InVitro International | 716.89k | 6.22k | 1.70m | 16.00 | 214.00 | 2.33 | -- | 2.38 | 0.0004 | 0.0004 | 0.0402 | 0.0321 | 1.15 | -- | -- | -- | 0.995 | 7.89 | 1.09 | 8.83 | -- | -- | 0.8676 | 5.90 | -- | -- | -- | -- | -5.11 | 1.33 | -87.77 | -16.14 | -- | -- |
Data as of May 20 2024. Currency figures normalised to 180 Life Sciences Corp's reporting currency: US Dollar USD
3.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 18.36k | 2.15% |
| Virtu Americas LLCas of 31 Dec 2023 | 4.01k | 0.47% |
| Tower Research Capital LLCas of 31 Mar 2024 | 3.44k | 0.40% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 750.00 | 0.09% |
| BlackRock Financial Management, Inc.as of 31 Mar 2024 | 22.00 | 0.00% |
| RBC Dominion Securities, Inc.as of 31 Mar 2024 | 11.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 4.00 | 0.00% |
| Semmax Financial Advisors, Inc.as of 31 Mar 2024 | 1.00 | 0.00% |
| Millennium Management LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| MM Asset Management, Inc.as of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
